comparemela.com

Latest Breaking News On - Paroxysmal disorders - Page 1 : comparemela.com

ResMed CEO: Weight-Loss Drugs Aren t Cutting Demand for Sleep Apnea Treatment

Chief Executive Mick Farrell expects the drugs will be used to complement proven treatments.

United statesSan diegoNovo nordisk wegovyMick farrellEli lillyNovo wegovyChris ratcliffe bloombergLilly zepboundUniversity of californiaNovo nordiskExecutive mick farrellAtul malhotraBill alpertArticle normalMedical equipment suppliesHealthcare life sciences

Elon Musk Has Used Illegal Drugs, Worrying Leaders at Tesla and SpaceX

Some executives and board members fear the billionaire’s use of drugs including LSD, cocaine, ecstasy, mushrooms and ketamine could harm his companies

Elon muskMotor vehiclesAlternative fuel vehiclesAerospace products partsHealthcare life sciencesAerospace defenseIndustrial goodsNorth americaUnited statesCorporate crime legal actionBoard of directorsCorporate industrial newsDrug substance use abusePolitical general newsSociety communityCrime legal action

Eli Lilly Stock Rises on Digital Healthcare Experience Launch

The pharmaceutical company says the website will serve patients in the U.S. living with migraines, obesity, and diabetes.

Emily dattiloDavid ricksNovo nordiskDrug administrationEli lillyArticle normalAgricultural machineryHealthcare life sciencesSpecialized drugs medicationsHormone productsIndustrial goodsDiabetes drugsNew products servicesCorporate industrial newsProducts servicesPolitical general news

How to Stay Asleep at Night: No Clocks, No Pets and No Netflix

Two years of pandemic disruptions are making it harder to fall and stay asleep, but changes to your night routine can help

Andrea petersenDow jones company incAll rightsMedia content distributionOnline service providersMedia entertainmentNorth americaUnited statesPolitical general newsEpisodic paroxysmal disordersPhysical fitnessSleep disordersLiving lifestyleMedical conditionsWsj pro comGeneral news

Neurocrine Biosciences trial failures may stunt momentum, analysts say

Company will halt development of experimental depression treatment

Evan david seigermanEiry robertsTakeda pharmaceutical coNeurocrine biosciences incNeurocrine biosciencesTakeda pharmaceuticalArticle normalBiotechnology servicesHealthcare life sciencesFinancial performanceAnalysts amp 39 comments recommendationsShare price movement disruptionsNew products servicesResearch developmentCorporate industrial newsProducts services

vimarsana © 2020. All Rights Reserved.